CAVATAK is a proprietary Coxsackievirus A21 (CVA21) developed by Viralytics. CVA21 is a naturally occurring “common cold” RNA virus which targets the intercellular adhesion molecule-1 (ICAM-1). CAVATAK CVA21 is a novel bio-selected formulation, which has potent oncolytic activity against in vitro cultures of cancer cells and in vivo xenografts of a number of cancers. It has demonstrated phase II trial safety in late stage melanoma patients with evidence of induction of immune cell infiltration into the tumours . Preclinical data in a mouse melanoma model suggest combinations of CAVATAK and anti-PD-1 or anti-CTLA-4 mAbs mediated significantly greater antitumor activity and offered greater survival benefits when compared to use of either agent alone .
- Andtbacka, R.H.I., Curti, B.D., Kaufman, H., Daniels, G.A., Nemunaitis, J.J., Spitler, L.E., Hallmeyer, S., Lutzky, J., Schultz, S.M., Whitman, E.D., et al. (2015). Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. J. Clin. Oncol. 33, suppl; abstr 9030.
- Au, G., Quah, M., Wong, Y., and Shafren, D. (2015). Combination of a novel oncolytic immunotherapeutic agent, CAVATAKTM (Coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model. In 9th International Conference on Oncolytic Virus Therapeutics, (Boston), p. O – 34.